Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral SCY-078 as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Trial Profile

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral SCY-078 as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Candidaemia; Candidiasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARES
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 15 Oct 2018 According to a SCYNEXIS media release, first patient has been dosed in the trial.
    • 09 Aug 2018 According to a SCYNEXIS media release, open-label FURI and CARES studies are designed for potential expedited regulatory approval via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).Also, preliminary data review from these trials is planned for the fourth quarter of 2018.
    • 04 Dec 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top